Bosh sahifaBMY • NYSE
add
Bristol Myers Squibb
Yopilish kursi
61,10 $
Kunlik diapazon
61,18 $ - 62,38 $
Yillik diapazon
42,52 $ - 63,33 $
Bozor kapitalizatsiyasi
126,87 mlrd USD
Oʻrtacha hajm
13,17 mln
Narx/foyda
18,03
Dividend daromadliligi
4,04%
Asosiy maydon
NYSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 12,50 mlrd | 1,30% |
Joriy xarajat | 5,47 mlrd | -13,56% |
Sof foyda | 1,09 mlrd | 1 409,72% |
Sof foyda marjasi | 8,69 | 1 398,28% |
Har bir ulushga tushum | 1,26 | -24,55% |
EBITDA | 4,54 mlrd | -2,17% |
Amaldagi soliq stavkasi | 26,12% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 10,67 mlrd | -1,71% |
Jami aktivlari | 90,04 mlrd | -2,77% |
Jami passivlari | 71,53 mlrd | -6,14% |
Umumiy kapital | 18,51 mlrd | — |
Tarqatilgan aksiyalar | 2,04 mlrd | — |
Narxi/balansdagi bahosi | 6,74 | — |
Aktivlardan daromad | 9,42% | — |
Kapitaldan daromad | 13,01% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 1,09 mlrd | 1 409,72% |
Operatsiyalardan naqd pul | 1,97 mlrd | -55,53% |
Sarmoyadan naqd pul | -1,46 mlrd | -643,88% |
Moliyadan naqd pul | -6,03 mlrd | -267,17% |
Naqd pulning sof oʻzgarishi | -5,51 mlrd | -324,45% |
Boʻsh pul | 669,62 mln | -84,21% |
Haqida
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Tashkil etilgan
1887
Sayt
Xodimlar soni
32 500
